Diane J Nugent

Summary

Affiliation: Children's Hospital of Orange County
Country: USA

Publications

  1. ncbi Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro
    Mei Chang
    Hemostasis and Thrombosis, Children s Hospital of Orange County, 455 S Main St, Orange, CA 92868, USA
    Blood 102:887-95. 2003
  2. ncbi Prophylaxis in rare coagulation disorders -- factor XIII deficiency
    Diane J Nugent
    Division of Hematology, Hemostasis Thrombosis Research, Children s Hospital of Orange County, Orange, CA 92868, USA
    Thromb Res 118:S23-8. 2006
  3. ncbi Factor XIII deficiency
    L Hsieh
    Division of Hematology, Children s Hospital of Orange County, Orange, CA 92868, USA
    Haemophilia 14:1190-200. 2008
  4. ncbi Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography
    Guy Young
    Department of Hematology, Children s Hospital of Orange County, Orange, California, USA
    Blood Coagul Fibrinolysis 18:547-53. 2007
  5. ncbi Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation
    Guy Young
    Department of Hematology, Children s Hospital of Orange County, Orange, California 92868, USA
    Blood Coagul Fibrinolysis 18:97-103. 2007
  6. ncbi Off-label use of rFVIIa in children with excessive bleeding: a consecutive study of 153 off-label uses in 139 children
    Guy Young
    Children s Hospital of Orange County, Orange, California, USA
    Pediatr Blood Cancer 53:179-83. 2009
  7. ncbi Identification of a novel regulatory element in the human interleukin 1 alpha (IL-1alpha) gene promoter
    Frank Zaldivar
    Immune and Inflammatory Disease Research, Children s Hospital of Orange County CHOC Research Institute, Orange, CA 92868, USA
    Cytokine 20:130-5. 2002
  8. ncbi Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits
    Guy Young
    Division of Hematology, Children s Hospital of Orange County, Orange, CA 92868, USA
    Perfusion 19:283-8. 2004
  9. ncbi Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency
    Amy E Lovejoy
    Department of Hematology, Children's Hospital of Orange County, Orange, CA 92868, USA
    Blood 108:57-62. 2006
  10. ncbi Genetic variants that affect platelet function
    Thomas J Kunicki
    Hematology Research, CHOC Children s Hospital, University of California, Irvine, Orange, USA
    Curr Opin Hematol 19:371-9. 2012

Collaborators

  • Guy Young
  • Thomas J Kunicki
  • Roshni Kulkarni
  • Mei Chang
  • Lynn K Boshkov
  • Veronica H Flood
  • M Moroi
  • Sachiko Kanaji
  • L Hsieh
  • Yann Cheli
  • Beatrice Jacquelin
  • Amy E Lovejoy
  • Michael D Tarantino
  • Frank Zaldivar
  • Kenichi Furihata
  • Melissa A Belvedere
  • Michael D Butine
  • Lisa C Weber
  • Tom C Reynolds
  • Mary L Davis
  • Henry Lynn
  • Frank E Shafer
  • Rachelle C Blain
  • Karen A Kalinyak
  • Salvatore J Bertolone
  • Jennifer E Visich
  • Susan M Pederson
  • Laura M Ishak
  • Kenji Izuhara
  • Taisuke Kanaji
  • Norio Komatsu
  • Karen Imfeld
  • Monique A Berman

Detail Information

Publications16

  1. ncbi Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro
    Mei Chang
    Hemostasis and Thrombosis, Children s Hospital of Orange County, 455 S Main St, Orange, CA 92868, USA
    Blood 102:887-95. 2003
    ..Taken together, these data indicate that autoantibodies against either platelet GPIb or platelet GPIIb/IIIa in ITP plasma not only are involved in platelet destruction, but may also contribute to the inhibition of platelet production...
  2. ncbi Prophylaxis in rare coagulation disorders -- factor XIII deficiency
    Diane J Nugent
    Division of Hematology, Hemostasis Thrombosis Research, Children s Hospital of Orange County, Orange, CA 92868, USA
    Thromb Res 118:S23-8. 2006
    ..The development of registries such as that in the USA will enable the different manifestations of the disease to be explored...
  3. ncbi Factor XIII deficiency
    L Hsieh
    Division of Hematology, Children s Hospital of Orange County, Orange, CA 92868, USA
    Haemophilia 14:1190-200. 2008
    ..Although there is a lifelong risk of bleeding, the prognosis is excellent when current prophylactic treatment is available using cryoprecipitate or plasma-derived FXIII concentrate...
  4. ncbi Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography
    Guy Young
    Department of Hematology, Children s Hospital of Orange County, Orange, California, USA
    Blood Coagul Fibrinolysis 18:547-53. 2007
    ..In conclusion, rFVIIa effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin, and should be considered for patients with excessive bleeding associated with these anticoagulants...
  5. ncbi Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation
    Guy Young
    Department of Hematology, Children s Hospital of Orange County, Orange, California 92868, USA
    Blood Coagul Fibrinolysis 18:97-103. 2007
    ..The reduced bleeding reported with DTIs versus heparin may relate to the fact that clots form with normal rigidity and elasticity...
  6. ncbi Off-label use of rFVIIa in children with excessive bleeding: a consecutive study of 153 off-label uses in 139 children
    Guy Young
    Children s Hospital of Orange County, Orange, California, USA
    Pediatr Blood Cancer 53:179-83. 2009
    ..Recombinant factor VIIa is a general hemostatic agent. Randomized trials have demonstrated effectiveness in adults; however, data in children are confined to case reports and series subject to publication bias...
  7. ncbi Identification of a novel regulatory element in the human interleukin 1 alpha (IL-1alpha) gene promoter
    Frank Zaldivar
    Immune and Inflammatory Disease Research, Children s Hospital of Orange County CHOC Research Institute, Orange, CA 92868, USA
    Cytokine 20:130-5. 2002
    ..These results will contribute to understanding of the regulatory mechanisms governing induction of the IL-1alpha gene and may lead to the isolation of a novel transcription factor...
  8. ncbi Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits
    Guy Young
    Division of Hematology, Children s Hospital of Orange County, Orange, CA 92868, USA
    Perfusion 19:283-8. 2004
    ..These results suggest that argatroban may be more efficacious than heparin for anticoagulation in ECMO. Additional studies are warranted to further evaluate argatroban in this setting...
  9. ncbi Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency
    Amy E Lovejoy
    Department of Hematology, Children's Hospital of Orange County, Orange, CA 92868, USA
    Blood 108:57-62. 2006
    ..Recombinant FXIII appears to be a safe and potentially effective alternative for FXIII replacement in patients with FXIII deficiency...
  10. ncbi Genetic variants that affect platelet function
    Thomas J Kunicki
    Hematology Research, CHOC Children s Hospital, University of California, Irvine, Orange, USA
    Curr Opin Hematol 19:371-9. 2012
    ....
  11. ncbi Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children
    Michael D Tarantino
    Comprehensive Bleeding Disorders Center, University of Illinois College of Medicine, Peoria, Illinois 61614, and Children s Hospital of Orange County, Orange, California, USA
    J Pediatr 148:489-94. 2006
    ....
  12. ncbi Thrombopoietin initiates demethylation-based transcription of GP6 during megakaryocyte differentiation
    Sachiko Kanaji
    Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    Blood 105:3888-92. 2005
    ..In every case, demethylation of the GP6 promoter correlated with an increase in mRNA level. Thus, megakaryocyte-specific expression of the GP6 gene is regulated, in part, by CpG demethylation, which can be directly initiated by TPO...
  13. ncbi Transcriptional and epigenetic regulation of the integrin collagen receptor locus ITGA1-PELO-ITGA2
    Yann Cheli
    The Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    Biochim Biophys Acta 1769:546-58. 2007
    ..Thus, selective CpG methylation of the ITGA1 promoter is a specific feature of alpha1beta1 regulation that coincides with the initiation of megakaryocyte differentiation...
  14. ncbi Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia
    Veronica H Flood
    Pediatric Stem Cell Transplant Program, Division of Pediatric Hematology Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Pediatr Blood Cancer 45:971-5. 2005
    ..We report three patients who received bone marrow transplantation (BMT) for type I GT and discuss the risk and management of anti-platelet antibodies...
  15. ncbi The influence of platelet glycoprotein polymorphisms on receptor function and risk for thrombosis
    Thomas J Kunicki
    The Scripps Research Institute, La Jolla, CA, USA
    Vox Sang 83:85-90. 2002
    ..The opportunity now exists to make significant inroads into the development of strategies for the prevention of thrombotic disease...
  16. ncbi Influence of platelet collagen receptor polymorphisms on risk for arterial thrombosis
    Kenichi Furihata
    Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    Arch Pathol Lab Med 126:305-9. 2002
    ..CONCLUSION: Genetic polymorphisms that influence the level or function of platelet collagen receptors need to be seriously considered as genetic risk factors for arteriothrombotic diseases...